FILING ANALYSIS · MONDAY, NOVEMBER 16
Insight Molecular Diagnostics Inc. IMDX — 8-K: Results of Operations and Financial Condition
neutral
The company reported Q3 2026 revenue of $559,000 and operating expenses declined as FDA-submission costs wound down, but the FDA review of GraftAssureDx is ongoing with a request for additional information, which may impact the stock price
The filing
8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →